Anti-MUC1 (AR20.5) is a murine monoclonal antibody targeting tumor-associated antigen MUC1. It has anti-tumor activity and can be used in research of potential cancer vaccine. MW :140.36 KD.

Anti-MUC17 is an IgG1 monoclonal antibody against MUC17, a membrane-bound protein highly expressed on the surface of intestinal cells. MW: 146.66 KD.

Anti-MUC17 is an IgG1 monoclonal antibody against MUC17, a membrane-bound protein highly expressed on the surface of intestinal cells. MW: 146.66 KD.

Anti-MUC17 is an IgG1 monoclonal antibody against MUC17, a membrane-bound protein highly expressed on the surface of intestinal cells. MW: 146.66 KD.

Anti-MUSK is a monoclonal IgG antibody against muscle-specific kinase (MuSK) with the potential to treat Myasthenia gravis. MW: 145.24 KD.

Anti-MUSK is a monoclonal IgG antibody against muscle-specific kinase (MuSK) with the potential to treat Myasthenia gravis. MW: 145.24 KD.

Anti-MUSK is a monoclonal IgG antibody against muscle-specific kinase (MuSK) with the potential to treat Myasthenia gravis. MW: 145.24 KD.

Anti-Myc magnetic beads kit is based on hydroxyl magnetic beads covalently coupling with mouse IgG1 monoclonal antibody.it is recommended to use for co-immunoprecipitation and protein purification.

Anti-Myc magnetic beads kit is based on hydroxyl magnetic beads covalently coupling with mouse IgG1 monoclonal antibody.it is recommended to use for co-immunoprecipitation and protein purification.

Anti-NGF / bNGF (AS2886401-00) is a monoclonal antibody targeting nerve growth factor (NGF). It holds tremendous potential for the management of osteoarthritis (OA). MW :139.0 KD.

Anti-NGF / bNGF (AS2886401-00) is a monoclonal antibody targeting nerve growth factor (NGF). It holds tremendous potential for the management of osteoarthritis (OA). MW :139.0 KD.

Anti-NGF / bNGF (AS2886401-00) is a monoclonal antibody targeting nerve growth factor (NGF). It holds tremendous potential for the management of osteoarthritis (OA). MW :139.0 KD.

Anti-NGF / bNGF (MEDI-578) is a monoclonal antibody targeting nerve growth factor (NGF). It holds tremendous potential for the management of osteoarthritis (OA). MW :145.42 KD.

Anti-NGF / bNGF (MEDI-578) is a monoclonal antibody targeting nerve growth factor (NGF). It holds tremendous potential for the management of osteoarthritis (OA). MW :145.42 KD.

Anti-NGF / bNGF (MEDI-578) is a monoclonal antibody targeting nerve growth factor (NGF). It holds tremendous potential for the management of osteoarthritis (OA). MW :145.42 KD.

Anti-Nogo Receptor / NgR is a monoclonal anti-NgR antibody with the potential to promote axonal regeneration. MW: 146.18 KD.

Anti-Nogo Receptor / NgR is a monoclonal anti-NgR antibody with the potential to promote axonal regeneration. MW: 146.18 KD.

Anti-Nogo Receptor / NgR is a monoclonal anti-NgR antibody with the potential to promote axonal regeneration. MW: 146.18 KD.

Anti-Nucleocapsid Antibody (N-18) is an antibody targeting the nucleocapsid protein of coronavirus. It is used in diagnosis with significantly associated with faster symptom resolution for COVID-19 patients. MW :150 KD.

Anti-Nucleocapsid Antibody (N-18) is an antibody targeting the nucleocapsid protein of coronavirus. It is used in diagnosis with significantly associated with faster symptom resolution for COVID-19 patients. MW :150 KD.

Anti-Nucleocapsid Antibody (N-18) is an antibody targeting the nucleocapsid protein of coronavirus. It is used in diagnosis with significantly associated with faster symptom resolution for COVID-19 patients. MW :150 KD.

Anti-Nucleocapsid Antibody (N-9) targets the nucleocapsid protein of coronavirus. It promotes IL-6 production in SARS-CoV-2-infected alveoli. It is used in acute respiratory distress syndrome MW :150 KD.

Anti-Nucleocapsid Antibody (N-9) targets the nucleocapsid protein of coronavirus. It promotes IL-6 production in SARS-CoV-2-infected alveoli. It is used in acute respiratory distress syndrome MW :150 KD.

Anti-Nucleocapsid Antibody (N-9) targets the nucleocapsid protein of coronavirus. It promotes IL-6 production in SARS-CoV-2-infected alveoli. It is used in acute respiratory distress syndrome MW :150 KD.

Anti-Nucleocapsid Antibody (N-P10) is a monoclonal antibody targeting the SARS-CoV-2 nucleocapsid protein (NP).It has strong potential for use in the clinical detection of SARS-CoV-2 infection, whether the virus is wild-type or a variant of concern. MW :150 KD.

Anti-Nucleocapsid Antibody (N-P10) is a monoclonal antibody targeting the SARS-CoV-2 nucleocapsid protein (NP).It has strong potential for use in the clinical detection of SARS-CoV-2 infection, whether the virus is wild-type or a variant of concern. MW :150 KD.

Anti-Nucleocapsid Antibody (N-P10) is a monoclonal antibody targeting the SARS-CoV-2 nucleocapsid protein (NP).It has strong potential for use in the clinical detection of SARS-CoV-2 infection, whether the virus is wild-type or a variant of concern. MW :150 KD.

Anti-Nucleocapsid Antibody (N-P10) is a monoclonal antibody targeting the SARS-CoV-2 nucleocapsid protein (NP).It has strong potential for use in the clinical detection of SARS-CoV-2 infection, whether the virus is wild-type or a variant of concern. MW :150 KD.

Anti-Nucleocapsid Antibody (N-P10) is a monoclonal antibody targeting the SARS-CoV-2 nucleocapsid protein (NP).It has strong potential for use in the clinical detection of SARS-CoV-2 infection, whether the virus is wild-type or a variant of concern. MW :150 KD.

Anti-Nucleocapsid Antibody (N-P10) is a monoclonal antibody targeting the SARS-CoV-2 nucleocapsid protein (NP).It has strong potential for use in the clinical detection of SARS-CoV-2 infection, whether the virus is wild-type or a variant of concern. MW :150 KD.

Anti-Orai1 is a human monoclonal anti-Orai1 antibody (mAb) with the potential to treat autoimmune diseases. MW: 143.86 KD.

Anti-Orai1 is a human monoclonal anti-Orai1 antibody (mAb) with the potential to treat autoimmune diseases. MW: 143.86 KD.

Anti-Orai1 is a human monoclonal anti-Orai1 antibody (mAb) with the potential to treat autoimmune diseases. MW: 143.86 KD.

Anti-Osteopontin is an antibody used in antigen-specific immunodetection in biological samples. MW: 145.5 kD.

Anti-Osteopontin is an antibody used in antigen-specific immunodetection in biological samples. MW: 145.5 kD.

Anti-Osteopontin is an antibody used in antigen-specific immunodetection in biological samples. MW: 145.5 kD.

Anti-OX2R / CD200R1 is a monoclonal antibody targeting CD200. It exhibited potential in regulating tissue inflammation during skin wound healing. MW :146.58 KD.

Anti-OX2R / CD200R1 is a monoclonal antibody targeting CD200. It exhibited potential in regulating tissue inflammation during skin wound healing. MW :146.58 KD.

Anti-OX2R / CD200R1 is a monoclonal antibody targeting CD200. It exhibited potential in regulating tissue inflammation during skin wound healing. MW :146.58 KD.

Anti-PAR2 is a antibody against Protease-Activated Receptor 2 (PAR2). MW: 145.5 kD.

Anti-PAR2 is a antibody against Protease-Activated Receptor 2 (PAR2). MW: 145.5 kD.

Anti-PAR2 is a antibody against Protease-Activated Receptor 2 (PAR2). MW: 145.5 kD.

Anti-PCLA is a fully human IgG4 monoclonal antibody targeting prostate cancer lipid-like antigen (PCLA) It can be used in treatment of prostate cancer. MW :145.52 KD.

Anti-PCLA is a fully human IgG4 monoclonal antibody targeting prostate cancer lipid-like antigen (PCLA) It can be used in treatment of prostate cancer. MW :145.52 KD.

Anti-PCLA is a fully human IgG4 monoclonal antibody targeting prostate cancer lipid-like antigen (PCLA) It can be used in treatment of prostate cancer. MW :145.52 KD.

Anti-PCSK9 (Boehringer anti-PCSK9) is a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) that prevents PCSK9-mediated degradation of the LDLR.MW: 146.42 kD.

Anti-PCSK9 (Boehringer anti-PCSK9) is a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) that prevents PCSK9-mediated degradation of the LDLR.MW: 146.42 kD.

Anti-PCSK9 (Boehringer anti-PCSK9) is a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) that prevents PCSK9-mediated degradation of the LDLR.MW: 146.42 kD.

Anti-PCSK9 (RG7652) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). It exhibits potential efficacy in coronary heart disease (CHD). MW :144.84 KD.